Xilio Therapeutics, Inc. (XLO)
NASDAQ: XLO · Real-Time Price · USD
1.280
+0.342 (36.46%)
At close: Dec 20, 2024, 4:00 PM
1.240
-0.040 (-3.13%)
After-hours: Dec 20, 2024, 7:59 PM EST
Xilio Therapeutics Employees
Xilio Therapeutics had 73 employees as of December 31, 2023. The number of employees decreased by 16 or -17.98% compared to the previous year.
Employees
73
Change (1Y)
-16
Growth (1Y)
-17.98%
Revenue / Employee
$63,288
Profits / Employee
-$860,315
Market Cap
56.27M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 73 | -16 | -17.98% |
Dec 31, 2022 | 89 | 15 | 20.27% |
Dec 31, 2021 | 74 | - | - |
Related Stocks
Company Name | Employees |
---|---|
CareCloud | 3,600 |
LakeShore Biopharma | 758 |
Repare Therapeutics | 179 |
Mural Oncology | 117 |
Scilex Holding Company | 105 |
Shattuck Labs | 75 |
Boundless Bio | 72 |
Kronos Bio | 63 |
XLO News
- 2 days ago - Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI - GlobeNewsWire
- 5 days ago - Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer - GlobeNewsWire
- 18 days ago - Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 weeks ago - Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid Tumors - GlobeNewsWire
- 6 weeks ago - Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results - GlobeNewsWire
- 7 weeks ago - Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting - GlobeNewsWire
- 2 months ago - Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting - GlobeNewsWire
- 4 months ago - Xilio Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference - GlobeNewsWire